Galmed Pharmaceuticals
GLMD
22 hedge funds and large institutions have $1.21M invested in Galmed Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 7 closing their positions.
51% more capital invested
Capital invested by funds: $804K → $1.21M (+$410K)
0% less ownership
Funds ownership: 0.06% → 0.05% (-0%)
12% less funds holding
Funds holding: 25 → 22 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
80% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$37.3K |
| 2 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$5.11K |
| 3 |
Jane Street
New York
|
+$4.84K |
| 4 |
SG
StoneX Group
New York
|
+$3.86K |
| 5 |
AWM
Accurate Wealth Management
Wesley Chapel,
Florida
|
+$393 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$21.8K |
| 2 |
Renaissance Technologies
New York
|
-$16K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$11.1K |
| 4 |
WWM
Western Wealth Management
Golden,
Colorado
|
-$10.7K |
| 5 |
VF
Virtu Financial
New York
|
-$7K |
GLMD Hedge Fund Activity: Q4 2022 in Review
22 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2022, worth a combined $1.21M — up 51% from $804K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GLMD and 4 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 2 added.
The largest buyer was Millennium Management, adding an estimated $37.3K. The largest seller was BVF Inc, cutting an estimated $21.8K.
- 22 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2022, down from 25 in Q3 2022.
- Funds reported $1.21M of Galmed Pharmaceuticals stock for Q4 2022, up 51% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of -3 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $37.3K added.
- The largest Galmed Pharmaceuticals seller in Q4 2022 was BVF Inc, an estimated $21.8K sold.
Based on aggregated 13F filings for Q4 2022.